Non-melanoma skin cancers, also referred to more specifically as 'keratinocyte cancers', are the most common class of skin cancers.[5] SCC is the second most common non-melanoma skin cancer worldwide (after basal cell carcinoma). SCCs are most frequently observed in photoexposed skin, often in those >40 years of age. Men have a higher incidence than women, and those with lighter skin types are at increased risk.[6] Incidence is highest near the equator and doubles with each 8° to 10° decrement in geographic latitude.[7] Of note, SCC is the most common skin cancer in patients with darker skin types and in organ transplant recipients taking immunosuppressive drugs. NIH: skin cancer treatment PDQ - health professional version external link opens in a new window Tropical Australia has the highest incidence of all types of skin cancer, with incidence of SCC of around 1/100 for the population of white people.[8] In England, a study of first primary SCC between 2013 and 2015 showed a rate of 77.3 per 100,000 person-years for male patients and 34.1 per 100,000 person-years for female patients.[9] In a study conducted in 1994, the lifetime risk of SCC in the US was estimated to be 9% to 14% in men, and 4% to 9% in women.[6] The approximate annual incidence is >100,000 in the US.[10] According to longitudinal studies in both the US and Canada, the incidence of SCC has increased by up to 200% over the past 20 years.[11]

BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.

To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.

You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.

Use of this content is subject to our disclaimer